journal article·2020-08Open access

Design and Characterization of a Novel Series of Geometrically Complex Intravaginal Rings with Digital Light Synthesis

Rima Janusziewicz, Sue J. Mecham, Kevin R. Olson, Soumya Rahima Benhabbour

Advanced Materials Technologies· Volume 5· Issue 8

Abstract

Abstract Intravaginal rings (IVRs) represent a sustained‐release approach to drug delivery and have long been used and investigated for hormones and microbicides delivery. For decades, IVRs have been manufactured by injection molding and hot‐melt extrusion with very limited design and material capabilities. Additive manufacturing (AM), specifically digital light synthesis (DLS), represents an opportunity to harness the freedom of design to expand control and tunability of drug release properties from IVRs. A novel approach to IVR design and manufacturing is reported that results in geometrically complex internal architectures through the incorporation of distinct unit cells using computationally aided design (CAD) software. A systematic approach is developed to design through the generation of an IVR library and the effects of these parameters are investigated on ring properties. The ability to precisely and predictably control the compressive properties of the IVR independent of the internal architecture with which control of drug release kinetics can be achieved is demonstrated, thus opening the door for a “plug‐and‐play” platform approach to IVR fabrication.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Additive Manufacturing and 3D Printing Technologies · 3D Printing in Biomedical Research · Bone Tissue Engineering Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Joint Department of Biomedical Engineering University of North Carolina at Chapel Hill and North Carolina State University Chapel Hill NC 27514 USA

Lineberger Comprehensive Cancer Center Institute for Nanomedicine University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA

Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA

Funding

National Center for Advancing Translational Sciences · National Institute of Allergy and Infectious Diseases

References (54)

Show source-provided references
1. 10.1016/j.contraception.2010.07.00810.1016/j.contraception.2010.07.008 ↗
2. 10.1016/j.addr.2015.04.01710.1016/j.addr.2015.04.017 ↗
3. 10.1097/QAD.000000000000145210.1097/QAD.0000000000001452 ↗
4. 10.1016/j.antiviral.2010.09.00310.1016/j.antiviral.2010.09.003 ↗
5. 10.1371/journal.pone.019726910.1371/journal.pone.0197269 ↗
6. 10.1016/j.ejogrb.2016.05.00910.1016/j.ejogrb.2016.05.009 ↗
7. 10.1016/S0015-0282(01)01689-210.1016/S0015-0282(01)01689-2 ↗
8. Phelps R. · 2014
9. 10.1016/j.contraception.2010.04.01210.1016/j.contraception.2010.04.012 ↗
10. 10.1016/j.maturitas.2015.02.26610.1016/j.maturitas.2015.02.266 ↗
11. 10.1002/jps.2320810.1002/jps.23208 ↗
12. 10.2147/DDDT.S13317010.2147/DDDT.S133170 ↗
13. 10.1056/NEJMoa150611010.1056/NEJMoa1506110 ↗
14. 10.1208/s12249-008-9073-510.1208/s12249-008-9073-5 ↗
15. 10.1016/j.addr.2016.01.01510.1016/j.addr.2016.01.015 ↗
16. 10.1007/978-3-642-21263-510.1007/978-3-642-21263-5 ↗
17. 10.1016/j.ijpharm.2018.08.05110.1016/j.ijpharm.2018.08.051 ↗
18. 10.1371/journal.pone.008850910.1371/journal.pone.0088509 ↗
19. 10.1016/j.ejps.2009.11.00710.1016/j.ejps.2009.11.007 ↗
20. 10.1128/AAC.02542-1310.1128/AAC.02542-13 ↗
21. 10.1128/AAC.00391-1610.1128/AAC.00391-16 ↗
22. 10.1371/journal.pone.018594610.1371/journal.pone.0185946 ↗
23. 10.1016/j.drudis.2018.11.01910.1016/j.drudis.2018.11.019 ↗
24. 10.1016/j.copbio.2016.03.01410.1016/j.copbio.2016.03.014 ↗
25. 10.1067/j.cpradiol.2015.07.00910.1067/j.cpradiol.2015.07.009 ↗
26. 10.1021/acs.chemrev.7b0007410.1021/acs.chemrev.7b00074 ↗
27. 10.1080/17434440.2017.136364710.1080/17434440.2017.1363647 ↗
28. 10.3109/03639045.2015.112074310.3109/03639045.2015.1120743 ↗
29. 10.1016/j.jmbbm.2016.04.04110.1016/j.jmbbm.2016.04.041 ↗
30. 10.1007/s11465-013-0248-810.1007/s11465-013-0248-8 ↗
31. 10.1016/j.ijpharm.2019.11872510.1016/j.ijpharm.2019.118725 ↗
32. 10.1016/j.ijpharm.2018.01.03610.1016/j.ijpharm.2018.01.036 ↗
33. 10.1371/journal.pone.018292910.1371/journal.pone.0182929 ↗
34. 10.1016/j.ejps.2015.11.00510.1016/j.ejps.2015.11.005 ↗
35. 10.1016/j.polymertesting.2018.09.02310.1016/j.polymertesting.2018.09.023 ↗
36. 10.1126/science.aaa239710.1126/science.aaa2397 ↗
37. 10.1073/pnas.160527111310.1073/pnas.1605271113 ↗
38. 10.1371/journal.pone.016251810.1371/journal.pone.0162518 ↗
39. 10.1016/j.jconrel.2018.03.02610.1016/j.jconrel.2018.03.026 ↗
40. Carbon I. · 2017
41. J. P.Rolland K.Chen J.Poelma J.Goodrich R.Pinschmidt J. M.DeSimone L. M.Robeson (Carbon Inc) US9676963B2 2017.
42. 10.1007/s00170-015-6994-510.1007/s00170-015-6994-5 ↗
43. 10.1111/cts.1231510.1111/cts.12315 ↗
44. 10.1016/j.contraception.2015.08.00710.1016/j.contraception.2015.08.007 ↗
45. 10.1371/journal.pone.014564210.1371/journal.pone.0145642 ↗
46. 10.1016/j.ijpharm.2019.01.02610.1016/j.ijpharm.2019.01.026 ↗
47. 10.1126/science.125229110.1126/science.1252291 ↗
48. 10.1073/pnas.150912011210.1073/pnas.1509120112 ↗
49. 10.1073/pnas.190581411610.1073/pnas.1905814116 ↗
50. Domb A. J. · 2014
51. 10.1016/j.ijpharm.2015.04.06910.1016/j.ijpharm.2015.04.069 ↗
52. 10.1016/j.addr.2007.05.01510.1016/j.addr.2007.05.015 ↗
53. 10.1038/s41392-017-0004-310.1038/s41392-017-0004-3 ↗
54. 10.1016/j.cad.2015.05.00210.1016/j.cad.2015.05.002 ↗